NCT04651790View on ClinicalTrials.gov

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

2,300

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

August 1, 2022

Study Completion Date

November 1, 2022

Conditions

Covid19Vaccines

Interventions

BIOLOGICAL

SARS-CoV-2 inactivated vaccine

The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.

Trial Locations (1)

7770228

Centro de Especialidades Médicas, Red de Salud UC Christus, Santiago

All Listed Sponsors

collaborator

Ministry of Health, Chile

OTHER_GOV

collaborator

Sinovac Biotech Co., Ltd

INDUSTRY

lead

Pontificia Universidad Catolica de Chile

OTHER

NCT04651790 - Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults | Biotech Hunter | Biotech Hunter